Gender-Affirming Care: Laws and Insurance Coverage

This article is provided for educational and informational purposes only. It does not constitute legal, financial, or tax advice, and no attorney-client relationship is formed by reading it. Laws, regulations, official guidance, and related information vary by jurisdiction, change frequently, and may have changed or become outdated since publication. Always verify current information with authoritative sources and consult a qualified professional about your specific circumstances. The author and publisher assume no liability for actions taken based on this information.

Contents

Identify the actual service, age, and coverage arrangement
What the Supreme Court decided in Skrmetti
A state insurance protection has its own scope
The Marketplace exclusion was vacated in August 2026
A separate Medicaid and CHIP rule has a future effective date
Section 1557: distinguish the statute from the vacated regulation
Make a coverage question specific enough to answer
Sources

Key Facts

Different services: Gender-affirming care is an umbrella term that can include counseling, social support, hormone-related treatment, and surgery.
Supreme Court: United States v. Skrmetti upheld Tennessee’s challenged restriction under equal-protection review; it did not enact a nationwide treatment ban.
Marketplace coverage: An August 14, 2026 federal court order vacated the rule provision excluding specified gender-affirming procedures from essential health benefits.
Medicaid and CHIP: A separate final rule schedules federal funding restrictions for specified pediatric procedures for October 13, 2026, with a limited hormone-therapy tapering provision.
Civil rights: The partial vacatur of the 2024 Section 1557 regulation did not repeal Section 1557 or erase the portions of that regulation left in force.

Gender-affirming care is not a single procedure or a single legal entitlement. The term can describe support and treatment ranging from counseling and social changes to medication and surgery.

For someone trying to understand access, the useful starting point is to separate three questions: which service is being sought, whether the relevant law permits it, and whether the particular payer will cover it. An answer about one of those questions may leave the others unresolved.

This overview addresses the U.S. legal framework, with a Washington insurance example; it does not provide a treatment recommendation or a state-by-state eligibility determination.

Identify the actual service, age, and coverage arrangement

The clinical umbrella is broader than the pharmaceutical and surgical procedures targeted by the new federal Medicaid and CHIP funding rule.

Counseling, a prescription, and surgery should therefore not be treated as interchangeable when reading a restriction or a coverage decision. Write down the exact service, the person’s age, the location of treatment, the insurer or public program, and the date care would be provided.

Age limits can also differ between programs: the new Medicaid funding restriction uses under 18, while the corresponding separate CHIP provision uses under 19.

A statement that a policy concerns “children” is not enough to identify which age cutoff applies. Likewise, ask which policy or statute is being cited rather than relying on a headline saying that care is either banned or protected.

What the Supreme Court decided in Skrmetti

On June 18, 2025, the Supreme Court decided United States v. Skrmetti, a challenge to Tennessee’s restrictions on puberty blockers and hormones for minors for specified gender-transition-related purposes.

The Court held that the challenged classifications were not subject to heightened scrutiny under the Fourteenth Amendment’s Equal Protection Clause and survived rational-basis review.

That holding rejected the equal-protection challenge before the Court; it did not require other states to enact Tennessee’s law or make adult treatment illegal nationwide.

The majority also expressly described its role as reviewing the constitutional question, rather than deciding the wisdom of the policy.

For a current access question, a citation to Skrmetti is therefore only part of the analysis. The particular state rule, the service it regulates, and any order addressing that rule still need to be identified.

A state insurance protection has its own scope

Washington illustrates why a federal court decision does not replace reading the applicable state insurance law. For health plans subject to RCW 48.43.0128 and issued or renewed on or after January 1, 2022, a health carrier may not deny or limit gender-affirming treatment meeting the statute’s prescription, medical-necessity, and accepted-standard-of-care conditions.

The statute prohibits categorical cosmetic or blanket exclusions for gender-affirming treatment and requires an experienced provider to review and confirm the appropriateness of an adverse benefit determination denying or limiting those services.

It also says that it does not mandate coverage of a service that is not medically necessary.

This is a Washington example, not a statement that every policy sold anywhere in the country carries the same protection. Ask whether the actual plan falls within the law being cited before treating a state coverage summary as an answer for an employer plan or a federal benefit program.

The Marketplace exclusion was vacated in August 2026

The 2025 Marketplace Integrity and Affordability rule included a provision preventing specified procedures from being classified as essential health benefits, or EHBs.

On August 14, 2026, the U.S. District Court for the District of Massachusetts held that provision unlawful and vacated it in California v. Kennedy.

The court found that HHS had changed EHBs without submitting the report and certification to Congress required by the ACA.

EHB classification matters because key ACA financial protections, including limits on annual out-of-pocket costs and restrictions on dollar limits for covered care, attach to EHB coverage.

The August order concerns that regulatory exclusion; it is not an individual claim approval or a ruling that every insurer must pay for every requested procedure.

A coverage inquiry still needs the plan documents and the specific denial reason. The Affordable Care Act guide explains the broader insurance framework.

A separate Medicaid and CHIP rule has a future effective date

CMS published final rule CMS-2451-F on August 13, 2026, with regulations scheduled to take effect October 13, 2026.

For the defined procedures, it prohibits payment under a Medicaid state plan for children under 18 and denies federal matching funds; it applies corresponding restrictions to separate CHIP for children under 19.

Its definition targets pharmaceutical or surgical interventions for the specified purpose and excludes procedures undertaken for other purposes, treatment of medically verifiable disorders of sexual development, and treatment of complications caused or worsened by the defined procedures.

The rule preserves federal funding for a tapering period of up to six months for beneficiaries receiving cross-sex hormone therapy as of October 13, 2026.

That is a limited transition provision, not a general six-month guarantee for new prescriptions or every type of treatment.

CMS explains that the rule does not prevent states from using state-only funds and does not remove mental-health services from coverage.

A coalition of states filed a lawsuit challenging this final rule on September 2, 2026.

The complaint requests judicial relief; filing it is not itself an order suspending the rule.

The October effective date was still in the future when this article was reviewed on September 9, 2026.

Recheck the operative rule and any court orders before relying on a future coverage date.

Section 1557: distinguish the statute from the vacated regulation

Section 1557 of the ACA prohibits specified forms of discrimination in covered health programs and activities, including programs receiving federal financial assistance.

In Tennessee v. Kennedy, a different case from Skrmetti, the district court on October 22, 2025, vacated specified portions of the 2024 implementing rule to the extent that they expanded Title IX’s definition of sex discrimination to include gender-identity discrimination.

HHS’s June 2, 2026 Federal Register notification says OCR cannot and will not investigate or enforce those vacated provisions to that extent.

The same notice confirms that the other portions of the 2024 rule remain in force.

The statute also preserves specified existing civil-rights remedies and state laws providing additional protections against discrimination.

These are different legal questions from whether a particular procedure is covered under an insurance contract. A statement that “all protections disappeared” or that “federal law guarantees every treatment” skips the actual provision, covered entity, and requested remedy.

Make a coverage question specific enough to answer

When a plan denies care, identify whether the stated reason concerns an excluded benefit, medical necessity, prior authorization, network access, or a legal restriction. Obtain the written decision and the relevant policy language, and keep a record of communications with the plan.

For plans subject to the ACA appeals regulation, an adverse-benefit notice must explain the reason for denial, including the denial code and the standard used, and describe available internal appeal and external review processes.

The regulation generally does not apply to grandfathered coverage, although separate external-review requirements apply to specified surprise-billing disputes involving that coverage.

An available appeal process does not establish that the requested treatment must be covered. Use the deadline and route in the actual notice, and ask which review process applies if the denial explanation is unclear.

The facts that most change the legal answer are the exact service, age, state law, payer, plan terms, and operative date. Keeping those facts separate makes it easier to distinguish a treatment restriction from a funding rule, a coverage exclusion, or a civil-rights issue.